These results indicated that effusanin E suppressed COX-2 promoter activity by inhibiting p50/p65 binding to the COX-2 promoter, thus leading to decreased cell survival, and proliferation of NPC cells. This evidence concerns the gene NFKB1 and nasopharyngeal carcinoma.